Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment

Cardiology

Volumn 117, Issue 4, 2011, Pages 296-300

  Karabay, Can Yucel ^a   Kocabay, Gonenc ^a   Kalayci, Arzu ^a   Zehir, Regaip ^a   Tanboga, Halil ^a  

^a Kartal Ko uyolu Yüksek Ihtisas Educational and Research Hospital   (Turkey)

Author keywords

Mitral regurgitation; Papillary muscle dyssynchrony; Trastuzumab

Indexed keywords

DOXORUBICIN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CLINICAL ASSESSMENT; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PAPILLARY MUSCLE; HUMAN; LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN; MITRAL VALVE REGURGITATION; MYOCARDIAL PERFUSION IMAGING; OUTCOME ASSESSMENT; PAPILLARY MUSCLE DYSSYNCHRONY; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MITRAL VALVE INSUFFICIENCY; PAPILLARY MUSCLES; TREATMENT OUTCOME;

EID: 79952049044     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323834     Document Type: Article

References (14)

1. Keefe DL: Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
2. Yeon CH, Pegram MD: Anti-erbB-2 antibody trastuzumab in the treatment of HER2- amplified breast cancer. Invest New Drugs 2005; 23: 391-409. (Pubitemid 41160088)
3. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-3131.
4. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221. (Pubitemid 34177427)
5. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826. (Pubitemid 46657379)
6. Martín M, Esteva FJ, Alba E, Khandheria B, Pérez-Isla L, García-Sáenz JA, Márquez A, Sengupta P, Zamorano J: Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist 2009; 14: 1-11.
7. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900-905. (Pubitemid 28446849)
8. Sparano JA: Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Semin Oncol 2001; 28: 20-27.
9. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez- Angulo AM, Hortobagyi GN, Esteva FJ: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115. (Pubitemid 46622286)
10. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C: Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-398.
11. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70. (Pubitemid 29411434)
12. Tu CM, Chu KM, Yang SP, Cheng SM, Wang WB: Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: A case report and literature review. Am J Emerg Med 2009; 27: 903.e1-e3.
13. Ho E, Brown A, Barrett P, Morgan RB, King G, Kennedy MJ, Murphy RT: Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: A speckle tracking echocardiographic study. Heart 2010; 96: 701-707.
14. Tigen K, Karaahmet T, Dundar C, Guler A, Cevik C, Basaran O, Kirma C, Basaran Y: The importance of papillary muscle dyssynchrony in predicting the severity of functional mitral regurgitation in patients with non-ischaemic dilated cardiomyopathy: A two-dimensional speckle-tracking echocardiography study. Eur J Echocardiogr 2010; 11: 671-676.